3:20 PM
 | 
Mar 06, 2009
 |  BC Extra  |  Company News

Orion pulls EU application for Stalevo in early PD

Orion (HSE:ORNAV; HSE:ORNBV) withdrew an application to extend the EU indication for Stalevo levodopa/carbidopa/entacapone to treat Parkinson's disease patients requiring the initiation of levodopa therapy. Orion said EMEA indicated that the data provided to date are insufficient for...

Read the full 174 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >